Диагностика и лечение рака молочной железы у мужчин (стр. 16 )

45.  Carey LA, Perou CM, Livasy CA, Dressler LG, Cowan D, Conway K, Karaca G, Troester MA, Tse CK, Edmiston S, Deming SL, Geradts J, Cheang MC, Nielsen TO, Moorman PG, Earp HS, Mil - likan RC: Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 2006; Vol.295: pp.2492-2502.

46.  Chakravarthy A, Kim CR. Post-mastectomy radiation in male breast cancer. Radiother Oncol 2002; Vol.65: pp.99-103.

47.  Clarke M, Collins R, Darby S, et al. Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005; Vol.366: pp.2087-106.

48.  Constantinou C, Fentiman IS. Diagnosis and treatment of male breast cancer. Breast Cancer Manage 2012. – Vol. 1(4). – pp. 295-304.

49.  Contractor KB, Kaur K, Rodtigues GS, Kulkarni DM, Singhal H. Male breast cancer: is the scenario changing. World rg. Oncol. 2008; Vol. 6: pp. 58.

50.  Crichlow RW. Carcinoma of the male rg Gynecol Obstet 1972;134:1011-1019.

51.  Cutuli B, Dilhuydy JM, De Lafontan B, et al. Ductal carcinoma in situ of the male breast. Analysis of 31 cases. Eur J Cancer 1997; Vol.33: pp.35-8.

52.  Cutuli B, Lacroze M, Dilhuydy JM et al. Male breast cancer: results of the treatments and prognostic factors in 397 cases. Eur. J. Cancer 1995; Vol.31A (12): pp.1960-1964.

53.  Cutuli B, Le-Nir CC, Serin D et al. Male breast cancer. Evolution of treatment and prognostic factors. Analysis of 489 cases. Crit. Rev. Oncol. Hematol. 2010; Vol.73: pp. 246-254.

54.  Dershaw DD, Fleischman RC, Liberman L, et al. Use of digital mammography in needle localization procedures. AJR Am J Roentgenol 1993; Vol.161: pp.559-62.

55.  Dershaw DD. Male mammography. AJR Am J Roentgenol 1986;Vol.146:pp.127-31.

56.  Donegan WL, Redlich PN, Lang PJ, Gall MT. Carcinoma of the breast in males: a multiinstitutional survey. Cancer 1998;Vol.83:pp.498-509.

57.  Doyle S, Steel J, Porter G, Imaging male breast cancer. Clin Radiol 2011; Vol.66: pp.1079-85.

58.  Duffaud F, Therasse P. New guidelines to evaluate the response to treatment in solid tumors. Bull Cancer. 2000; Vol.87(12): pp.881-6.

59.  Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009; Vol.45(2): pp.228-47.

60.  Evans DGR, Susnerwala I, Dawson J, Woodward E, Maher ER, Lalloo F. Risk of breast cancer in male BRCA2 carriers. J Med Genet 2010; Vol.47: pp.710-1. Published online June 28, 2010 in advance of journal print.

61.  Fackenthal JD, Marsh DJ, Richardson AL et al. Male breast cancer in Cowden syndrome patients with germline PTEN mutations. J Med Genet 2001. - Vol. 38. – pp.159-164.

62.  Fentiman IS, Fourquet A, Hortobagyi GN. Male breast cancer. Lancet 2006; Vol.367: pp.595-604.

63.  Fisher B, Anderson S, Bryant J, et al. Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. N Engl J Med 2002; Vol.347: pp.1233-41.

64.  Fodor PB. Breast cancer in a patient with gynecomastia. // Plast. rg. – 1989. – Vol.84. – p.976-979.

65.  Fogh S, Kachnic LA, Goldberg SI, Taghian AG et al. Localized therapy for male breast cancer: functional advantages with comparable outcomes using breast conservation. Clinical Breast Cancer 2013. – Vol.13, No.5. – pp. 344-349

66.  Forloni F, Giovilli M, Pecis С et al. Pituitary prolactin-secreting microadenoma combined with bilateral breast cancer in a 45-year-old male. J. Endocrinol. Invest. 2001; Vol.24(6): pp. 454-459.

67.  Freedman BC, Keto J et al. Screening mammography in men with BRCA mutations: is there a role? The Breast Journal 2012. – Vol. 18 (1). – pp. 73-75.

68.  Gancberg D, Järvinen T, di Leo A et al. Evaluation of HER-2/NEU protein expression in breast cancer by immunohistochemistry: an interlaboratory study assessing the reproducibility of HER-2/NEU testing. Breast Cancer Res. Treat. 2002; Vol.74(2): pp. 113-120.

69.  Ge Y, Sneige N, Eltorky MA, Wang Z, Lin E, Cong Y, et al. Immunohistochemical characterization of subtypes of male breast carcinoma. Breast Cancer Res 2009; Vol.11: p. R28.

70.  Giordano SH, Cohen DS, Buzdar AU et al. Breast carcinoma in men: a population-based study. Cancer 2004; 101:51-57.

71.  Giordano SH, Perkins GH, Broglio К et al. Adjuvant systemic therapy for male breast carcinoma. Cancer 2005; Vol. 104(11): pp. 2359-2364.

72.  Giordano SH, Valero V, Buzdar AU, Hortobagyi GN. Efficacy of anastrozole in male breast cancer. Am. J. Clin. Oncol. 2002; Vol. 25(3): pp. 235-237.

73.  Gnerlich JL, Deshpande AD, Jeffe DB, Seelam S, Kimbuende E, Margenthaler JA. Poorer survival outcomes for male breast cancer compared with female breast cancer may be attributable to in-stage migration. Ann Surg Oncol 2011; Vol.18: pp.1837-44.

74.  Goldhirsch A, Ingle JN, Gelber RD, et al. Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer. Ann Oncol 2009; Vol.20: pp.1319-29.

75.  Golshan M, Rusby J, Dominguez F, Smith BL. Breast conservation for male breast carcinoma. Breast 2007; Vol. 16(6): pp. 653-656.

76.  Goss PE, Reid C, Pintilie M, Lim R, Miller N. Male breast carcinoma: a review of 229 patients who presented to the Princess Margaret Hospital during 40 years: 1955-1996. Cancer 1999; Vol. 85(3): pp. 629-639.

77.  Gu G-L, Wang S-L, Wei X-M, et al. Axillary metastasis as the first manifestation of male breast cancer: a case report. Cases J 2008; Vol.1: p.285.

78.  Guiahi M, Gabram SGA, Albain KS, Camacho P, Krishnamachari B, Rajan P. Clinical Factors used to support prophylactic mastectomy for male BRCA2 mutation rgery 2006;Vol.139:pp.704-6.

79.  Günhan-Bilgen I, Bozkaya H, Ustün EE, et al. Male breast disease: clinical, mammographic, and ultrasonographic features. Eur J Radial 2002; Vol.43: pp.246-55.

80.  Hayashi H, Kimura M, Yoshimoto N, et al. A case of HER2-positive male breast cancer with lung metastases showing a good response to trastuzumab and paclitaxel treatment. Breast Cancer 2009; Vol.16: pp.136-40.

81.  Hill AD, Borgen PI, Cody HS. Sentinel node biopsy in male breast cancer. Eur J Surg Oncol 1999; Vol.25: pp.442-3.

82.  Hines SL., Tan WW, Yasrebi M, DePeri ER, Perez EA. The role of mammography in male patients with breast symptoms. Mayo Clin. Proc. 2007; Vol.82(3): pp. 297-300.

83.  Hultborn R, Hanson C, Köpf I, Verbiené I, Warnhammar F., Weimarck A. Prevalence of Klinefelter's syndrome in male breast cancer patients. Anticancer Res. 1997; Vol.17(6D): pp. 4293-4297.

84.  Ihemelandu CU, Leffall LD Jr, Dewitty RL, Naab TJ, Mezghebe HM, Makambi KH, Adams-Campbell L, Frederick WA: Molecular breast cancer subtypes in premenopausal and postmenopausal African-American women: age-specific prevalence and survival. J Surg Res 2007; Vol.143: pp.109-118.

85.  Jaiyesimi IA, Buzdar AU, Sahin AA, Ross M A. Carcinoma of the male breast. Ann. Intern. Med. 1992; Vol.117(9): pp. 771-777.

86.  Janes SE, Lengyel JA, Singh S, Aluwihare N, Isgar B. Needle core biopsy for the assessment of unilateral breast masses in men. Breast 2006;Vol.15(2): pp. 273-275.

87.  Johansson I, Nilsson C, Berglund P, Strand C, Jönsson G, Staaf J, et al. High- resolution genomic profiling of male breast cancer reveals differences hidden behind the similarities with female breast cancer. Breast Cancer Res Treat 2010; Vol.129: pp.747- 60.

88.  Jӧnsson G, Staaf J, Vallon-Christersson J, Ringner M, Holm K, Hegardt C, et al. Genomic subtypes of breast cancer identified by array comparative genomic hybridization display distinct molecular and clinical characteristics. Breast Cancer Res 2010; Vol.12: p. R42.

89.  Korde LA, Zujewski JA, Kamin L, et al. Multidisciplinary meeting on male breast cancer: summary and research recommendations. J Clin Oncol 2010; Vol.28: pp.2114-22.

90.  Krause W. Male breast cancer - an andrological disease: risk factors and diagnosis. Andrologia 2004; Vol.36(6): pp. 346-354.

91.  Kwiatkowska E, Teresiak M, Filas V, Karczewska A, Breborowicz D, Mackiewicz A. BRCA2 mutations and androgen receptor expression as independent predictors of outcome of male breast cancer patients. Clin. Cancer Res. 2003; Vol.9(12): pp. 4452-4459.

92.  Lanitis S, Filippakis G, Al Mufti R, et al. Breast conserving surgery with preservation of the nipple-areola complex as a feasible and safe approach in male breast cancer: a case report. J Med Case Reports 2008; Vol.2: p.126.

93.  Levy-Lahad E, Friedman E. Cancer risks among BRCAl and BRCA2 mutation carriers. Br. J. Cancer 2007; Vol.96(1): pp.11-15.

94.  Liede A, Karlan BY, Narod SA. Cancer risks for male carriers of germline mutations in BRCAl or BRCA2: a review of the literature. J. Clin. Oncol. 2004; Vol.22(4): pp. 735-742.

95.  Lopez M, Di Lauro L, Papaldo P, Lazzaro B. Hormonal treatment of disseminated male breast cancer. Oncology 1985; Vol.42(6): pp. 345-349.

96.  Lyman GH, Giuliano AE, Somerfield MR et al. American Society of Clinical Oncology guideline recommendations for sentinel lymph node biopsy in early-stage breast cancer. J. Clin. Oncol. 2005; Vol. 23(30): pp. 7703-7720.

97.  Mauras N, O'Brien КО, Welch S et al. Estrogen suppression in males: metabolic effects. J. Clin. Endocrinol. Metab. 2000; Vol.85(7): pp. 2370-2377.

98.  McConnell JD, Roehrborn CG, Bautista OM et al. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hypertrophy. N. Engl. J. Med. 2003; Vol.349(25): pp. 2387-2398.